Definition: In this task, you are given a text of many news articles seperated by special token "|||||". Your task is to summarize them.
Input: At the WSJDLive 2015 conference, Theranos founder and CEO Elizabeth Holmes discusses her company's proprietary technologies, the FDA's inspection of its facilities, and the assertion that her company was too quick to market its products. ||||| Focused crawls are collections of frequently-updated webcrawl data from narrow (as opposed to broad or wide) web crawls, often focused on a single domain or subdomain. ||||| Theranos, the $9 billion startup that wants to revolutionize blood tests, issued a detailed rebuttal on its website to the Wall Street Journal Thursday morning. 
  
 The rebuttal is a response to an explosive story published in the Journal last week. 
  
 The Journal's report alleged that Theranos is struggling to make its 'revolutionary' in-house technology actually work, and reports that only about 10% of Theranos' blood tests use its technology, with the rest of the tests being carried out using traditional blood-testing tech. Even the company's own employees have concerns about Theranos' blood tests. 
  
 Theranos, whose goal is to make clinical testing cheaper and faster, issued a point-by-point rebuttal to the Journal's story. The company touches on its interactions with the FDA, the accuracy of Theranos' tests, and the fact that only a fraction of its tests are performed with finger-sticks. 
  
 Here are some of the points Theranos makes in its rebuttal: 
  
 It's no secret that only some of Theranos' tests are finger-stick tests, as opposed to venous draws. "We have consistently said in public statements, on our website, and to our customers in Wellness Centers that some of our tests are performed on venous draws, in part because we have been becoming a full-service laboratory," Theranos says in its statement. 
  
 "We have consistently said in public statements, on our website, and to our customers in Wellness Centers that some of our tests are performed on venous draws, in part because we have been becoming a full-service laboratory," Theranos says in its statement. Theranos stands by the fact that its blood tests are accurate. The company writes: " With each FDA filing, Theranos is showing that our finger-stick tests are just as accurate as venous draws, starting with our first FDA clearance this summer." 
  
 Theranos says its proficiency-testing protocols are complicit with regulations — and the company has initiated conversations with the FDA. "Theranos has explained our process to our regulators, and proficiency testing at Theranos meets the regulatory requirements," Theranos says. 
  
 Since the Journal's story last week, Theranos' accuracy has come into question by some people who have taken its tests, including ex-Apple exec Jean-Louis Gassee. 
  
 In its rebuttal, Theranos also tries to call into question the sourcing used by John Carreyrou, the Pulitzer Prize-winning reporter who wrote the story, by calling attention to the fact that he used anonymous sourcing in his story. From a journalistic perspective, anonymous sourcing is often helpful, if not necessary, to get access to sources (often employees or former employees) who otherwise wouldn't speak out of fear of violating non-disclosure agreements or retribution from the company they're speaking out against. 
  
 "From his very first interactions with Theranos, the reporter made abundantly clear that he considered Theranos to be a target to be taken down, and not simply the subject of an objective news story," Theranos says in its post. "The articles that appeared last week are the inevitable product of that approach." 
  
 The Journal released a statement on Wednesday after Theranos founder Elizabeth Holmes spoke at the WSJ's Digital conference. "We note that Ms. Holmes sought to challenge the reliability of our sources, but it remains the fact that she doesn’t know from whom the information for our articles was gathered," the Journal said in its statement. "We assure her and our readers that our sources were well positioned to know the information they provided about Theranos, and they were vetted before publication." 
  
 You can read Theranos' full rebuttal here. ||||| Photo Advertisement Continue reading the main story 
  
 LAGUNA BEACH, Calif. — Being the self-proclaimed leader of a medical revolution can have its downside. 
  
  
  
  
  
  
  
  
  
 Elizabeth Holmes, a 31-year-old Stanford dropout who became a billionaire by starting the blood testing laboratory Theranos, is now waging a public battle to defend her reputation and that of her closely watched Silicon Valley company. 
  
 Her campaign began shortly after two articles published in The Wall Street Journal last week questioned the accuracy of the company’s blood tests and the extent to which Theranos is using unique technology. 
  
 Ms. Holmes now says she is planning to release a 16-page point-by-point rebuttal of the articles, a document that concludes by accusing the articles’ author of having an agenda that considered Theranos “a target to be taken down.” 
  
 The rebuttal even dissects the motivations of various people quoted in the articles. 
  
 “We’ll put this out there and let people judge for themselves what the facts are,” Ms. Holmes said on Tuesday in an interview with The New York Times. 
  
 Ms. Holmes ventured into the lion’s den on Wednesday, defending her company in an onstage interview here at The Wall Street Journal’s own WSJ.DLive technology conference, where she drew applause for showing up. 
  
 “We know the integrity of what we’ve done,” Ms. Holmes said at the conference. She characterized criticisms of her company as “a few people who want to say bad things about us.” 
  
 Ms. Holmes has complained that critics are out to get her company because it threatens the traditional lab industry. 
  
 But the company, which is highly secretive about its technology, has not announced any new policies in response to the criticism. 
  
 Theranos, Ms. Holmes said, had no immediate plans to do what skeptics say would most persuade them: publish data in peer-reviewed medical journals showing that its test results were as accurate as those of more established laboratories. 
  
 She said that other institutions testing Theranos’s products might eventually publish papers, but that the company, for now, was concentrating on getting its tests approved by the Food and Drug Administration. That, she said, would provide even better external validation. One test, for herpes simplex 1 virus, has already been approved, and the company has submitted 120 others to the agency. 
  
 Advertisement Continue reading the main story 
  
 “We’ve never been against peer review,” Ms. Holmes said in the interview with The Times. “We decided that the studies we were doing would be the F.D.A. submissions.” 
  
 Theranos, based in Palo Alto, Calif., says that it can do many different medical tests using only a tiny amount of blood taken with a finger prick. It has also said that it used proprietary lab equipment to deliver results much faster and more cheaply than traditional blood tests, which in some cases require several vials of blood to be drawn from the arm and several days to get a result. 
  
 Photo 
  
 Theranos lists the prices of its tests on its website, and they are typically far lower than most other labs’ prices. 
  
 Investors have poured money into the privately held company, which was recently valued at more than $9 billion. Ms. Holmes, who started the company at age 19 and has said that she devotes nearly every waking hour to it, has graced the covers of magazines including Fortune, Inc. and The New York Times’s T magazine, and she is a frequent presence on the conference circuit. She recently appeared at Vanity Fair’s New Establishment Summit alongside Facebook’s chief executive, Mark Zuckerberg, and Walt Disney’s chief, Robert A. Iger. 
  
 Advertisement Continue reading the main story 
  
 Advertisement Continue reading the main story 
  
 The Wall Street Journal article last week, citing an unnamed former senior employee, said that as recently as December, Theranos was routinely performing only about 15 of the more than 200 tests it offered using its proprietary equipment, with the rest being performed on standard machines bought from laboratory equipment vendors. 
  
 In its rebuttal, which Theranos plans to post on its website the company said that it performed more than 80 of the tests using its own technology that month. It said that 57 percent of customers in the fourth quarter of last year had blood drawn from a finger prick. 
  
 Last week, the company said that it was not using finger pricks at the moment — except for the herpes test — because it was following F.D.A. advice that its “nanotainer,” the tiny tube that holds the blood from finger pricks, needed regulatory approval as a medical device. The company is now seeking that approval. But Ms. Holmes said that the need to get approval for the tube did not reflect on the accuracy of the machines that analyze the blood samples. 
  
 A spokesman for The Wall Street Journal thanked Ms. Holmes for attending the conference but added, “Nothing said at the conference by Ms. Holmes refutes the accuracy” of the articles. 
  
 The Wall Street Journal is not the only one raising questions. Jean-Louis Gassée, a former senior executive at Apple, wrote in a blog post on Sunday that the results of two tests from Theranos raised alarms about his health when results for the same tests on the same day from Stanford Hospital did not. Moreover, the Theranos results varied more widely from one day to the next than those from Stanford, he said. 
  
 In January, William Quirk, an analyst at Piper Jaffray, wrote that a member of his team had gone for common blood tests at a Theranos center in Phoenix and at two hospitals. The Theranos results came back in 70 hours, compared with about 25 hours for the other two labs, despite Theranos’s claim to deliver “results in hours, not days.” 
  
 At the conference here, Bill Maris, the head of venture capital firm GV, formerly known as Google Ventures, told The Times that when the company was thinking of investing in Theranos, one of his employees went to a Walgreens pharmacy for a Theranos blood test and was later asked to return to give more blood. Theranos did not seem able to deliver on its promise of testing small amounts of blood, he said. Business Insider reported earlier on Mr. Maris’s remarks. 
  
 Ms. Holmes said that she had never spoken with Mr. Maris and that GV had once “reached out to us and we said no to meeting them.” She said a few anecdotes did not cast doubt on the technology, asserting that the company has done more than 3.5 million tests. 
  
 Ms. Holmes said the company has always said that some tests would require more conventional blood draws, though even for those, she said, Theranos tends to use smaller needles and smaller amounts of blood than other labs. She said the company wanted to provide a complete roster of tests, so it began offering tests that could not yet be performed with finger samples on its own machines. 
  
 Still, this caveat about conventional blood draws has often seemed more like a footnote for a company that has at times proclaimed, “Say goodbye, big bad needle.” Certainly, the impression from interviews and numerous articles has been that Theranos performed the vast majority of tests using finger pricks and its proprietary machines. 
  
 “The general public was under the impression that Theranos was further along in their development than they currently are,” said Eric Lakin, an analyst at DeciBio, a consulting and market research firm that follows the diagnostics industry. 
  
 Mr. Lakin said he thought that Ms. Holmes, in her talk at the conference, “directly addressed many of the concerns people raised.” 
  
 Nonetheless, he said, “There’s still going to be doubts about why won’t you compare your results directly” with those from established labs like Quest Diagnostics and LabCorp. While Theranos does post some performance data on its website, it is not sufficient, he said. |||||
Output:
A 31-year-old tech billionaire and Stanford dropout has gone from gracing the covers of magazines to defending her revolutionary blood-testing company against charges that its work is inaccurate and misleading, the New York Times reports. According to the Wall Street Journal, Elizabeth Holmes founded Theranos 12 years ago because she had a fear of needles. The company sought to use new technology to perform more than 200 types of blood tests using only finger pricks. But last week the Journal published two stories calling out Theranos for performing only one test—for herpes—with blood from finger pricks and using traditional blood draws and technology for everything else. It also cited former employees who claimed Theranos diluted its tiny blood draws to make them work with traditional technology, leading to greater risks of errors. Holmes addressed those claims onstage during a Journal-sponsored tech conference Wednesday, the Times reports. “We know the integrity of what we’ve done,” she told the audience. According to the Journal, Holmes claimed the company is in a "pause period" with its unique blood-testing technology while it awaits FDA approval. She denied any faults with performance or accuracy. Business Insider reports Theranos issued a full rebuttal of the Journal's claims Thursday. The rebuttal questions the motivations of the Pulitzer Prize-winning journalist who wrote the original articles, as well as his anonymous sources. "From his very first interactions with Theranos, the reporter made abundantly clear that he considered Theranos to be a target to be taken down," the rebuttal states. But, as the Times notes, the Journal isn't Holmes' only trouble; a few other prominent people have also raised questions about Theranos tests. (Click to see how Holmes was being covered in the press just last year.)